MedTrace Logo

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

NCT00144482 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2009-02-02

No results posted yet for this study

Summary

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Conditions

  • Chemotherapy Induced Anemia

Interventions

DRUG

recombinant human erythropoietin

36000IU（0.5mL）s.c./week for 8 weeks

DRUG

recombinant human erythropoietin placebo

0 IU(0.5mL)s.c./week for 8 weeks

Sponsors & Collaborators

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Yoshiharu Ishikura · Chugai Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-03-31
Completion
2005-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144482 on ClinicalTrials.gov